That's great and may be possible. By then, with the need for more money for testing, the stock will have dropped due to the failures, will RS and basically current shares will be almost worthless. Management failed to get it right and the stock holders will pay for it.
They try but designing a trial for a new chemistry/approach means there are a lot of unknowns, as well as the usual time and financial considerations, the ability to attract patients, etc. Running a 6 or 12 week study will take a lot longer and cost a lot more than a 2 week study, and patients might be less willing to sign up. VTGN had their focus on fast onset so they designed a trial for that.
What they didn't know at the time was that opioid activation is necessary for Ketamine's ultra fast onset. If that was known previously, VTGN and other companies could have saved themselves a lot of trouble. The results of the Stanford study became known in 2018 -
News 
Market Data 
Discover 
